ORIGINAL RESEARCH A Deep Learning Model Combining Multimodal Factors to Predict the Overall Survival of Transarterial Chemoembolization

Zhongqi Sun^b¹, Xin Li¹, Hongwei Liang¹, Zhongxing Shi², Hongjia Ren³

¹Department of Radiology, the Second Affiliated Hospital of Harbin Medical University, Harbin, 150086, People's Republic of China; ²Department of Interventional Radiology, the Second Affiliated Hospital of Harbin Medical University, Harbin, 150086, People's Republic of China; ³School of Information Science and Engineering, Yanshan University, Qinhuangdao, 066004, People's Republic of China

Correspondence: Zhongqi Sun, Email sunzhongqi2021@163.com; Hongjia Ren, Email renhj@ysu.edu.cn

Background: To develop and validate an overall survival (OS) prediction model for transarterial chemoembolization (TACE).

Methods: In this retrospective study, 301 patients with hepatocellular carcinoma (HCC) who received TACE from 2012 to 2015 were collected. The residual network was used to extract prognostic information from CT images, which was then combined with the clinical factors adjusted by COX regression to predict survival using a modified deep learning model (DLOP_{Combin}). The DLOP_{Combin} model was compared with the residual network model (DLOP_{CTR}), multiple COX regression model (DLOP_{Cox}), Radiomic model (Radiomic), and clinical model.

Results: In the validation cohort, DLOP_{Combin} shows the highest TD AUC of all cohorts, which compared with Radiomic (TD AUC: 0.96vs 0.63) and clinical model (TD AUC: 0.96 vs 0.62) model. DLOP_{Combin} showed significant difference in C index compared with $DLOP_{CTR}$ and $DLOP_{Cox}$ models (P < 0.05). Moreover, the $DLOP_{Combin}$ showed good calibration and overall net benefit. Patients with $DLOP_{Combin}$ model score ≤ 0.902 had better OS (33 months vs 15.5 months, P < 0.0001).

Conclusion: The deep learning model can effectively predict the patients' overall survival of TACE.

Keywords: deep learning, transarterial chemoembolization, hepatocellular carcinoma

Introduction

Liver cancer is the third leading cause of cancer-related deaths worldwide.^{1,2} Hepatocellular carcinoma (HCC) is the most common type of liver cancer.³ Patients with early HCC are therapeutic with transplantation, resection, and ablation, and have an overall 5-year survival rate reaching 70-80%.⁴ However, approximately 80% of patients are in the Barcelona Clinic Liver Cancer staging classification B (BCLC B) at the time of diagnosis, with significantly decreased survival.⁵ Currently, transcatheter arterial chemoembolization (TACE) is the first-line therapy for patients in BCLC B stage.⁶ Nevertheless, the objective response rate for TACE was 52.5% and the 3-year overall survival (OS) was 40.4%.⁷ Accordingly, understanding the prognosis of TACE patients and predicting the survival period of TACE patients is crucial in the overall treatment, which can stratify the risk of diseases and help clinicians to make more personalized decisions, such as determining the follow-up time and planning the treatment programme.

Previous studies have suggested several clinical factors are associated with the prognosis of TACE, including tumor size, tumor numbers, and alpha-fetoprotein (AFP) levels.^{8–10} Moreover, relevant researchers have developed scoring systems that integrate various clinical information, such as the BCLC B subclassification, albumin-bilirubin (ALBI) grade, and neutrophil-to-lymphocyte ratio.^{11–13} The above methods can assist clinicians in predicting survival to some extent, whereas, they implicitly assume that the relationship between predictor variables and output results is linear, which may not be a valid assumption, and few studies incorporate radiomic information. CT examination contains not only tumor size and imaging features, but also more information about the prognosis of the primary tumor.^{14,15} Studies have shown that illustrates that the imaging phenotype at the macro level is closely related to the tissue phenotype at the

385

micro level, and even closely related to molecular pathways and genetic changes.^{16,17} Obviously, high-dimensional information mined from CT can be used to predict the survival of TACE patients.

In recent years, image-based deep learning methods have shown promising potential for predicting survival, it constructs a model with a large number of hidden layers, automatically extract features, and find various complex nonlinear relationships between input and output after repeated correction.^{18,19} Therefore, deep learning can be used to predict the survival problem of TACE based on CT images.²⁰ However, in these studies, the prediction model did not account for important confounders (such as preoperative clinical variables and postoperative treatment response after TACE), particularly, postoperative treatment response is an important predictor of TACE survival.^{21,22} In other words, the deep learning model based on CT images and clinical factors (preoperative and postoperative) to predict the survival of TACE is worthy of further study.

In this study, we aim to develop a deep learning survival prediction model ($DLOP_{Combin}$) based on preoperative CT images, clinical factors, and postoperative treatment responses to predict the overall survival (OS) prognosis of TACE in HCC patients in the BCLC B stage, and compare it with other models, to finally provide a reference for individual decision making after TACE and overall treatment.

Materials and Methods

The study was approved by the institutional review board of Harbin Medical University (KY2020-267) and performed by the ethical standards outlined in the Declaration of Helsinki. Written informed consent was waived as this study was collected retrospectively, but patient data is kept strictly confidential.

Patients

A total of 301 patients from the Second Hospital of Harbin Medical University between January 2012 to December 2015 were enrolled. Eligible patients were those primary patients diagnosed with HCC and treated with TACE for the first time. Exclusion criteria were radiotherapy, ablation, or other systemic treatment before TACE, cancers other than HCC, lymph node or distant metastases, lack of necessary clinical information, poor CT image affecting analysis, and no available survival data. All patients were randomly divided into a training cohort and a validation cohort in a ratio of 8:2 (Figure S1).

Patient demographic and clinical characteristics (including age, gender, diabetes, cirrhosis, hepatitis), laboratory variables (including alpha-fetoprotein (AFP), alanine aminotransferase (ALT), aspartate aminotransferase (AST), albumin (ALB), total bilirubin (TBIL), microvascular infiltration (MVI), BCLC B subclassification, albumin-bilirubin grade (ALBI), child-pugh score were obtained from the electronic medical records. Tumor characteristics (number, size, location) were recorded from radiology reports.

CT Image Acquisition

All enrolled patients underwent enhanced abdominal CT scans before treatment. Detailed CT scans are given in <u>Appendix E1</u>. CT images of all patients were reviewed by radiologists with 8 and 10 years of diagnostic imaging experience, respectively, without knowledge of clinical information and follow-up data.

Follow-Up and Treatment Response

The endpoint was overall survival, defined as the time between the date of initial TACE and death from causes relevant to this study. To ensure that OS was evaluated in the context of clinical practice, patients received subsequent radiotherapy, surgery, or sorafenib after TACE treatment according to clinical guidelines. Data from patients lost to follow-up or surviving at the last follow-up (January 2022) were considered as censored data.

<u>Appendix E2</u> for details of the TACE process. CT enhancement /MRI follow-up was performed every 4–6 weeks after TACE until disease stabilization. The treatment response of target lesions was assessed according to the modified Response Evaluation Criteria in Solid Tumors (mRECIST1.1).²³ Treatment response was assessed independently by 2 radiologists with \geq 8 years of experience, and results were categorized as complete response (CR), partial response (PR), stable disease (SD), and progressive disease (PD).

Model Construction

The workflow is shown in Figure 1.To integrate CT images and clinical data, we propose an improved resnet101 deep learning model ($DLOP_{Combin}$) <u>Appendix E3</u>. The model consists of three main parts: CT feature extraction, clinical feature integration and multimodal features fusion.

- (1) CT feature extraction Input CT image size is set to 224*224 pixels. High-dimensional semantic information was extracted from CT images by stacking residual convolution blocks, and features were reduced to one dimension by globally averaging pooling layers with the following structure: two convolutional layers, two pooling layers two, two BatchNormalization layers and one residual connection structure. To visualize the figure, a thermal peak activation map was generated using Grad CAM.
- (2) Clinical feature integration We trained a multilayer perceptron classifier (MLP) consisting of three fully connected 16, 32, and 64 hidden units to splice clinical factors after univariate and multivariate COX regression analysis.
- (3) Multimodal features fusion The CT feature is 2048 dimensions and the clinical feature is 64 dimensions. CT features and clinical features were placed into the DLOP_{Combin} fully connected layer, which consisted of five perceptrons. Represents the survival probability of the following time intervals: 0–365 days, 365–730 days, 730–1095 days, and 1095–1460 days, respectively. The final output layer is defined as [cumulative survival probability (product of the first three perceptrons)] *100. The final output of the model represents an approximate probability of a 3-year survival (1095 days).

Model Comparison

To verify the validity of the deep learning model proposed in this study, $DLOP_{Combin}$ was compared with the following four survival prediction models (<u>Appendix E4</u>).

- 1) DLOP_{CTR} model: The above obtained image target areas were applied to Resnet101 to build a TACE survival prediction model for liver cancer based only on CT images.
- 2) DLOP_{Cox} model: The output of the DLOP_{CTR} model was used as a separate variable and combined with clinical factors to build a multi-factor COX regression prediction model.



Figure I Workflow of TACE patient survival prediction model based on deep learning (DLOPcombin).

- 3) Radiomic model: The image information was transformed into high-dimensional data, and the survival prediction model was established through image normalization, delineation of interest region, feature extraction, correlation coefficient calculation and LASSO COX dimension reduction.
- 4) Clinical model: Univariate and multivariate cox regression analyses were used to predict independent risk factors for OS, and clinical models were constructed for clinical variables with statistical differences.

Statistical Analysis

Patient characteristics were compared using the x^2 test or Fisher test. Univariate and multifactorial COX regression analyses were performed to screen for the factors most associated with survival. To assess the discriminatory performance of DLOP, we calculated the Harrell C index. The performance of the model was evaluated using time-dependent area under the receiver operating characteristic curves (TD AUCs) and positive and negative predictive values were calculated. The calibration curves were plotted to assess the degree of overfitting of the model. The Youden index was used to calculate the optimal cut-off point and to classify patients into high-risk and low-risk classes. The clinical efficacy of the model was analyzed using DCA curves. The discriminatory performance of DLOP_{Combin} was benchmarked and the student's *t*-test was used to compare the C indices of other models. DeLong test is used to compare TD AUC between models. The false discovery rate (FDR) method is used for calibration. In addition, the output of DLOP_{Combin} was used as a separate variable to reconcile multivariate risk ratios (HRs) using Cox regression analysis.

All statistical analyses were performed using R software. P < 0.05 were considered statistically different Appendix E5.

Results

Patient Characteristics

A total of 301 patients with HCC were included in our retrospective study. The detailed results of patients in the training cohort (n=241), validation cohort (n=60) are summarized in Table 1. There was no significant difference between the training cohort and the validation cohort in all patient characteristics.

	Training Cohort	Validation Cohort	Р
	(n=241)	(n=60)	-
Age	61.00(57.00-71.00)	60.00(58.00-68.00)	0.5609
Gender			0.8527
Male	182(75.5)	46(76.7)	
Female	59(24.5)	14(23.3)	
Portal Hypertension			0.8527
No	182(75.5)	46(76.7)	
Yes	59(24.5)	14(23.3)	
Diabetes			0.9519
No	196(81.3)	49(81.7)	
Yes	45(18.7)	11(18.3)	
Cirrhosis			0.2223
No	84(34.9)	26(43.3)	
Yes	157(65.1)	34(56.7)	
Hepatitis			0.0024
No-HBV	33(13.7)	0 (0)	
HBV	208(86.3)	60(100)	
AFP	142.84(27.72-415.59)	130.88(10.76-689.58)	0.6993
AST	65.00(27.00-169.00)	59.00(34.00-137.00)	0.5855
ALT	42.00(28.00-61.00)	35.50(24.50–56.50)	0.2044

Table I Baseline Demographic and Clinical Characteristics

(Continued)

	Training Cohort (n=241)	Validation Cohort (n=60)	Ρ
ALB	37.80(34.00-41.50)	38.20(33.65-41.05)	0.8036
TBIL	20.40(13.20-29.50)	19.45(11.70-27.70)	0.4248
Tumor number			0.6227
> 2	100(41.5)	27(45.0)	
≤ 2	141(58.5)	33(55.0)	
Tumor size	48.00(31.00-78.00)	42.25(24.50-65.50)	0.1446
Tumor location			0.1549
Left	45(18.7)	7(11.7)	
Right	153(63.5)	46(76.7)	
Others	43(17.8)	7(11.7)	
MVI			0.1124
No	109(45.2)	34(56.7)	
Yes	I 32(54.8)	26(43.3)	
ALBI grade			0.2147
l grade	I 30(53.9)	27(45.0)	
2~3 grade	(46.)	33(55.0)	
Child-Pugh score			0.6436
Α	172(71.4)	41(68.3)	
B~C	69(28.6)	19(31.7)	
BCLC B subclassification			0.0622
I	99(41.0)	20(33.3)	
2	89(36.9)	19(31.7)	
3	25(10.4)	14(23.3)	
4	28(11.7)	7(11.7)	

Table I (Continued).

Abbreviations: AFP, alpha-fetoprotein; AST, aspartate aminotransferase; ALT, alanine aminotransferase; ALB, albumin; TBIL, total bilirubin; HBV, hepatitis B virus; MVI, microvascular infiltration; ALBI, albumin-bilirubin.

Development and Validation of DLOPCombin

After adjusting for variables in the multivariate Cox regression model in the training cohort, treatment response, MVI, ALBI score and BCLC B subclassification were significant prognostic factors in predicting OS (Table 2). The TD AUC of DLOP_{Combin} in predicting 3-year survival in the training and validation cohorts were 0.98 (95% CI: 0.94, 1.00) and 0.96 (95% CI: 0.88, 1.00), respectively (Table 3 and Figure 2A and B). The C-index of the DLOP_{Combin} for OS prognosis was 0.90 (95% CI: 0.85, 0.95) in the training cohort and 0.88 (95% CI: 0.80, 0.96) in the validation cohort (Table 4). Calibration curves show good agreement between observations and predictions (Figure 2C and D). The Youden index is 0.902, Figure 3A and B show that patients with a score \leq 0.902 showed significantly better OS than those with scores higher than 0.902.

Comparison of DLOP_{Combin} with Other Models

In the validation cohort, the TD AUC of $DLOP_{CTR}$ was 0.89 (95% CI: 0.80, 0.98) and the C-index was 0.75 (95% CI: 0.75, 0.89) (Table 3 and Table 4). In addition, multifactorial COX regression analysis of the training set showed that the output variables of $DLOP_{CTR}$ were significantly associated with OS (HR: 0.14; 95% CI: 0.10, 0.21; P < 0.01) (Table S1). For the clinically adjusted model ($DLOP_{Cox}$), the C-index was 0.79 (95% CI: 0.69, 0.89) for the DLOPcox training set and 0.77 (95% CI: 0.70, 0.84) for the validation set (Table 4).

Five radiomic features were selected by LASSO COX regression analysis to construct the radiomic model (<u>Table S2</u> and <u>Figures S2</u>, <u>S3</u>). The TD AUC of the Radiomic model was 0.70 (95% CI: 0.61, 0.79) and 0.63 (95% CI: 0.49, 0.76)

Variable	Univariate Analysis		Multivariate Analysis			
	HR (95% CI)	Р	HR (95% CI)	Р		
Age	0.97(0.96–0.99)	< 0.05 0.99 (0.97–1.02)		0.62		
Gender	1.00 (0.78–1.40)	0.78				
Portal Hypertension	0.79 (0.59–1.10)	0.11				
Diabetes	0.89 (0.65-1.2)	0.47				
Cirrhosis	0.87 (0.68–1.1)	0.28				
Hepatitis	0.75 (0.51–1.1)	0.14				
Child-Pugh score	1.447 (1.078–1.941)	0.01	1.36 (0.98–1.88)	0.67		
AFP	1.59(0.78–3.26)	0.20				
AST	1.93(0.71–5.26)	0.20				
ALT	2.58(0.69–9.74)	0.16				
ALB	0.74(0.36-1.54)	0.42				
TBIL	1.16(0.48–2.75)	0.75				
Tumor number	1.12 (0.88–1.43)	0.35				
Tumor size	1.00 (1.00–1.00)	0.74				
Tumor location						
Left	Reference					
Right	0.18 (0.86-1.7)	0.56				
Others	0.18 (0.79–1.8)	0.56				
MVI	1.742 (1.325–2.290)	<0.0001	1.42 (1.05–1.92)	0.02		
ALBI grade	2.125 (1.618–2.791)	<0.0001	1.89 (1.41–2.54)	<0.0001		
BCLC B subclassification						
Reference						
2	1.347 (1.078–1.941)	0.0543	1.53 (1.11–2.10)	0.01		
3	1.866 (1.172–2.971)	0.0086	2.25 (1.39–3.65)	0.001		
4	4.704 (2.926–7.562)	<0.0001	3.74 (2.29–6.10)	<0.0001		
Treatment response	0.52 (0.37-0.72)	< 0.05	0.04 (0.293-0.969)	0.04		

Table 2 Univariate and Multivariate Cox Regression Analysis of Clinical Factors in theTraining Cohort

Note: *P* < 0.05 indicates statistically significant.

Abbreviations: HR, hazard ratio; CI, confidence interval.

Table 3 Performance of the Model in Predicting the Prognosis of HCC Patients in the Training Cohort and the Validation Cohort

Variable	Training Cohort					Validation Cohort						
	TD AUC (95% CI)	ACC	PRE	REC	PPV	NPV	TD AUC (95% CI)	ACC	PRE	REC	PPV	NPV
DLOPCombin	0.98 (0.94, 1.00)	0.96	0.81	0.97	0.92	0.98	0.96 (0.88, 1.00)	0.93	0.84	0.92	0.90	0.92
DLOPCTR	0.92 (0.88, 0.95)	0.87	0.75	0.91	0.82	0.91	0.89 (0.80, 0.98)	0.85	0.72	1.00	0.8	0.95
DLOP _{Cox}	0.91 (0.86, 0.96)	0.86	0.72	0.91	0.85	0.93	0.89 (0.81, 0.97)	0.84	071	1.00	0.92	0.81
Radiomics	0.70 (0.61, 0.79)	0.74	0.47	0.69	0.69	0.68	0.63 (0.49, 0.76)	0.70	0.43	0.50	0.65	0.68
Clinical	0.66 (0.60, 0.72)	0.64	0.40	0.85	0.82	0.70	0.62 (0.59, 0.65)	0.59	0.42	0.78	0.76	0.65

Notes: Data are presented as time-dependent areas under the receiver operating characteristic curve (TD AUC) and Harrell C-Index, with 95% CI in parentheses. Deep Learning Model combining CT Images and Clinical Factors (DLSPcombin); Deep Learning Survival Prediction Model Based on CT Images (DLSP_{CTR}); DLSP_{CTR} as a separate variable combined with clinical factors in a multifactor COX model (DLSP_{COX}).

for the training and validation sets, respectively. In addition, the clinical model showed the lowest TD AUC: 0.66 (95% CI: 0.60, 0.72) (Table 3). The details as shown in Appendix E6.

The TD AUC of $DLOP_{Combin}$ was 7.9%, 7.9%, 52.4%, and 54.8% higher than those of $DLOP_{CTR}$, $DLOP_{cox}$, Radiomic, and clinical model, respectively. DeLong test results show that $DLOP_{Combin}$ model is significantly different from other models (Figure 4A–D). The NPV of $DLOP_{Combin}$ was higher than those of the above four models (Table 3).



Figure 2 Performance of different survival prediction models. Time-dependent receiver operating curves under the area for 3-year survival of patients (A) training cohort (B) validation cohort. Calibration curves of the model (C) training cohort (D) validation cohort.

Furthermore, $DLOP_{Combin}$ has a significant difference with other models in C index (P < 0.05) (Table 4). In addition, the DCA in the validation cohort showed that the $DLOP_{Combin}$ model had higher overall net benefit than other models (Figure 5A and B). Furthermore, the Kaplan-Meier analysis of OS of BCLC substage is shown in Figure S3.

Activation Mapping of the DLOPCombin

Activation profiles of HCC tumors showed that the deep learning survival prediction model had different phenotypic patterns among patients. As shown in Figure 6, the characteristic maps of patients with longer survival periods showed richer activity in the tumor internal heat map (Figure 6A1-3). In contrast, in patients with poor TACE response, the peritumor heat map activity was relatively complex (Figure 6B1-3). An example of a prediction error is shown (Figure 6C1-3), which may indicate that different activation patterns predict TACE postharcoma.



Figure 3 Kaplan-Meier estimates of overall survival according to the Youden index of DLSPcombin categorized high- and low-risk groups (A) training cohort (B) validation cohort.

Discussion

We developed a deep learning survival prediction model (DLOP_{Combin}) based on CT images and postoperative treatment responses for the first time to successfully predict 3-year survival in patients with HCC undergoing TACE. The model performed well in the training set and validation set. The results were better than DLOP_{Cox} and DLOP_{CTR} models (C index: 0.98 vs 0.92, P < 0.001; 0.96 vs 0.89, P < 0.001). In addition, the TD AUC of DLOP_{Combin} was higher than the Radiomic model (0.96 vs 0.63; P < 0.001) and clinical model (0.96 vs 0.62; P < 0.001).

CT images contain some important information reflecting HCC.¹⁵ It shows the status of the tumor and contains information about the tumor perimeter, which is 5 cm around the tumor and is an important cause of death in patients with TACE. Previous studies have shown that CT-driven parameters have been shown to correlate with disease prognosis or severity. In this regard, deep learning can not only extract important prognostic information directly from CT images through end-to-end learning, but also learn more complex decision boundaries by training complex multivariate functions to fit the data.^{18,19} In this paper, our constructed CT-only deep learning model successfully extracts important features from CT images, quantifies them into values that are correlated with patient outcomes and showed good performance. However, further in-depth study showed that the $DLOP_{Combin}$ model after combining CT images and clinical variables yielded a model with the best performance.

Parameter	Training Cohort			Validation Cohort			
	Harrell C index	Р	P⁺	Harrell C index	Р	P ⁺	
	0.90(0.85, 0.95)			0.88(0.80, 0.96)			
DLOPCTR	0.78(0.72, 0.84)	0.04	0.05	0.75(0.75, 0.89)	0.03	0.04	
DLOP _{Cox}	0.79(0.69, 0.89)	0.02	0.04	0.77(0.70, 0.84)	0.02	0.03	
Radiomics	0.61(0.51, 0.71)	< 0.01	0.03	0.59(0.50, 0.68)	< 0.01	0.03	
Clinical	0.60(0.45, 0.75)	< 0.01	0.03	0.56(0.48, 0.64)	< 0.01	0.03	

Table 4 Discrimination Performance and Calibration of the Survival Prediction Model

Notes: Discrimination refers to Harrell C index, student test was used for comparison between C indices, and FDR was used for calibration, Data in parentheses are 95% confidence intervals. *P* values indicate that $DLOP_{Combin}$ is used as the benchmark for comparison with other models. *P* ⁺values indicate FDR calibration of P value.



Figure 4 Results of the DeLong test between the different models (A) training cohort (B) validation cohort. Results of the FDR after calibration of the p-value (C) training cohort (D) validation cohort.

In the past, the prediction of survival in TACE patients by clinical factors has been extensively explored. For example, Campani et al used different clinical variables to study survival in TACE with some success.^{24–26} Jung found that treatment response was an important variable in predicting prognosis in TACE,²¹ and similarly this paper found that TACE treatment response was an independent prognostic factor associated with survival through multivariate COX regression studies. In fact, treatment response contains important information after TACE, including the status of the target lesion, lymph node condition, and the presence of new lesions, and may provide more prognostic information than pre-TACE treatment variables.²²

More interestingly, two different approaches, deep learning and Cox regression, were tried in integrating CT images with postoperative treatment response. The results reveal that the performance of deep learning is higher than that of Cox regression, which may be mainly due to the following points: (1) the deep model represents CT images and clinical features in different network layers, which is easy to classify and identify the information; (2) the deep learning model is a nonlinear framework, which can fit the data better by optimizing and adjusting the parameters. To further validate the performance of the proposed DLOP_{Combin} model in terms of survival prognosis, we also built a radiomics model, and the results showed that the DLOP_{Combin} model outperformed the radiomics model in predicting the survival prognosis of TACE.Jiang also obtained the same results, and the analysis may be due to the fact that the multilayer structure in the



Figure 5 Decision curve analysis of the (A) training cohort (B) validation cohort.

deep learning neural network can automatically learn hierarchical rich image features to improve robustness.²⁷ At the same time, the deep learning model avoids redundant proposal generation, caused by the lower learning efficiency.

In our study, we controlled for several important confounders, including the number and size of HCC, by univariate and multifactorial cox regression analyses that were not shown in prognostic models. Previous studies have shown that the number and size of HCC are important prognostic factors for survival.²⁸ The reason for not including these factors in this study is that treatment response contains both variables and there is linear overlap in multivariate COX analysis. Our study also showed that BCLC B subclassification, albumin-bilirubin (ALBI) grade and microvascular infiltration are clinical factors associated with TACE prognosis, which is consistent with previous studies.^{29–31} Finally, clinical model as also has some predictive power for the prognosis of TACE. However, in our study, the TD AUC of the clinical model validation set was 0.62. The analysis may be that the clinical model ignores the information of image heterogeneity, which may be the reason for the decreased performance.

Our study has some limitations. Firstly, as a retrospective study, treatment route was an important confounding factor that was difficult to control for, including potential differences in immunotherapy and adjuvant therapy. Although treatment was performed according to treatment guidelines, some variability may still exist in actual clinical practice. Secondly, although we proposed a CT image activation map, the mechanism of DLOP_{Combin} model to predict TACE prognosis is unclear and not better explained at present, and the mechanism of deep learning characterization needs to be further investigated. Thirdly, regarding differences in cancer biology, our model was developed and validated in the context of the majority of HBV-associated HCC patients, but hepatitis C and alcoholism are the leading causes of HCC in Western countries. This may lead to differences in the choice of TACE treatment options in clinical practice, therefore, the model should be validated in a Western setting. Finally, this study is a single-center study and lacks an external validation set. In the future, we will expand the sample size and introduce an external validation set to further improve the reliability and generalization of the study.

In conclusion, deep learning models based on preoperative CT and postoperative treatment response for predicting disease-free survival in HCC patients are important tools for preoperative risk stratification and can facilitate clinical decision making in the era of precision medicine.



Figure 6 Examples of CT images (A), Heatmap (B), and their corresponding gradient-class activation maps (C) on the validation cohort. On both the heat map and the gradient class activation map, red areas indicate that the area may be associated with a high probability of survival for the patient, while blue lesions indicate a low probability of survival. (A) A 64-year-old woman with 4 years of survival after TACE and Ct-based deep learning survival prediction model activation focused on the tumor region. (B) A 52-year-old male with no internal tumor activation and a disease-free survival of 240 days. (C) The patient with the incorrect prediction, a 48-year-old male, survived 397 days after surgery. The model predicted low risk; however, death occurred after 1254 days.

Acknowledgment

Thanks to Dr. Wang Guokun from the Second Affiliated Hospital of Harbin Medical University for his assistance in the manuscript revision process.

Disclosure

The authors report no conflicts of interest in this work.

References

- 1. Vogel A, Meyer T, Sapisochin G, et al. Hepatocellular carcinoma. Lancet. 2022;400(10360):1345–1362. doi:10.1016/S0140-6736(22)01200-4
- Kelley RK, Greten TF. Hepatocellular carcinoma—origins and outcomes. *New Engl J Med.* 2021;385(3):280–282. doi:10.1056/NEJMcibr2106594
 Dash S, Aydin Y, Widmer KE, et al. Hepatocellular carcinoma mechanisms associated with chronic HCV infection and the impact of direct-acting antiviral treatment. *J Hepatocell Carcinoma.* 2020;7:45–76. doi:10.2147/JHC.S221187
- 4. Cai X. Laparoscopic liver resection: the current status and the future. Hepatobiliary Surg Nutr. 2018;7(2):98-104. doi:10.21037/hbsn.2018.02.07

- Chow PKH, Gandhi M, Tan SB, et al. SIRveNIB: selective internal radiation therapy versus sorafenib in Asia-pacific patients with hepatocellular carcinoma. J Clin Oncol. 2018;36(19):1913–1921. doi:10.1200/JCO.2017.76.0892
- 6. Geraldes FO. Annual congress of the European Association of nuclear medicine 2021. Lancet Oncol. 2021;22(12):1655. doi:10.1016/S1470-2045(21)00634-3
- 7. Lencioni R, de Baere T, Soulen MC, et al. Lipiodol transarterial chemoembolization for hepatocellular carcinoma: a systematic review of efficacy and safety data. *Hepatology*. 2016;64(1):106–116. doi:10.1002/hep.28453
- 8. Sheng Y, Wang Q, Liu HF, et al. Preoperative nomogram incorporating clinical factors, serological markers and LI-RADS MRI features to predict early recurrence of hepatocellular carcinoma treated with transarterial chemoembolization. *Acad Radiol.* 2022;30:1288–1297. doi:10.1016/j. acra.2022.10.020
- 9. Katayama K, Imai T, Abe Y, et al. Number of nodules but not size of hepatocellular carcinoma can predict refractoriness to transarterial chemoembolization and poor prognosis. J Clin Med Res. 2018;10(10):765–771. doi:10.14740/jocmr3559w
- 10. Liu S, Li H, Guo L, et al. Tumor size affects efficacy of adjuvant transarterial chemoembolization in patients with hepatocellular carcinoma and microvascular invasion. *Oncologist.* 2019;24(4):513–520. doi:10.1634/theoncologist.2018-0305
- 11. Biolato M, Gallusi G, Iavarone M, et al. Prognostic ability of BCLC-B subclassification in patients with hepatocellular carcinoma undergoing transarterial chemoembolization. *Ann Hepatol.* 2018;17(1):110–118. doi:10.5604/01.3001.0010.7542
- 12. Johnson PJ, Berhane S, Kagebayashi C, et al. Assessment of liver function in patients with hepatocellular carcinoma: a new evidence-based approach-The ALBI grade. J Clin Oncol. 2015;33(6):550–558. doi:10.1200/JCO.2014.57.9151
- 13. Chon YE, Park H, Hyun HK, et al. Development of a new nomogram including neutrophil-to-lymphocyte ratio to predict survival in patients with hepatocellular carcinoma undergoing transarterial chemoembolization. *Cancers*. 2019;11(4):509. doi:10.3390/cancers11040509
- 14. Kourou K, Exarchos TP, Exarchos KP, et al. Machine learning applications in cancer prognosis and prediction. *Comput Struct Biotechnol J*. 2014;13:8–17. doi:10.1016/j.csbj.2014.11.005
- 15. Lee G, Lee HY, Park H, et al. Radiomics and its emerging role in lung cancer research, imaging biomarkers and clinical management: state of the art. Eur J Radiol. 2017;86:297–307. doi:10.1016/j.ejrad.2016.09.005
- 16. Aerts HJ, Velazquez ER, Leijenaar RT, et al. Decoding tumour phenotype by noninvasive imaging using a quantitative radiomics approach. *Nat Commun.* 2014;5(1):4006. doi:10.1038/ncomms5006
- 17. Lee SH, Yim SY, Jeong YS, et al. Consensus subtypes of hepatocellular carcinoma associated with clinical outcomes and genomic phenotypes. *Hepatology*. 2022;76(6):1634–1648. doi:10.1002/hep.32490
- Shi JY, Wang X, Ding GY, et al. Exploring prognostic indicators in the pathological images of hepatocellular carcinoma based on deep learning. GUT. 2021;70(5):951–961. doi:10.1136/gutjnl-2020-320930
- 19. Saillard C, Schmauch B, Laifa O, et al. Predicting survival after hepatocellular carcinoma resection using deep learning on histological slides. *Hepatology*. 2020;72(6):2000–2013. doi:10.1002/hep.31207
- 20. Wang H, Liu Y, Xu N, et al. Development and validation of a deep learning model for survival prognosis of transcatheter arterial chemoembolization in patients with intermediate-stage hepatocellular carcinoma. *Eur J Radiol.* 2022;156:110527. doi:10.1016/j.ejrad.2022.110527
- 21. Jung J, Joo JH, Kim SY, et al. Radiologic response as a prognostic factor in advanced hepatocellular carcinoma with macroscopic vascular invasion after transarterial chemoembolization and radiotherapy. *Liver Can.* 2021;11(2):152–161. doi:10.1159/000521227
- 22. Han G, Berhane S, Toyoda H, et al. Prediction of survival among patients receiving transarterial chemoembolization for hepatocellular carcinoma: a response-based approach. *Hepatology*. 2020;72(1):198–212. doi:10.1002/hep.31022
- Cucchetti A, Serenari M, Sposito C, et al. Including mRECIST in the Metroticket 2.0 criteria improves prediction of hepatocellular carcinoma-related death after liver transplant. J Hepatol. 2020;73(2):342–348. doi:10.1016/j.jhep.2020.03.018
- Campani C, Vitale A, Dragoni G, et al. Time-varying mHAP-III is the most accurate predictor of survival in patients with hepatocellular carcinoma undergoing transarterial chemoembolization. *Liver Cancer*. 2021;10(2):126–136. doi:10.1159/000513404
- 25. Park C, Kim JH, Kim PH, et al. Imaging predictors of survival in patients with single small hepatocellular carcinoma treated with transarterial chemoembolization. *Korean J Radiol*. 2021;22(2):213–224. doi:10.3348/kjr.2020.0325
- 26. Fu S, Lai H, Huang M, et al. Multi-task deep learning network to predict future macrovascular invasion in hepatocellular carcinoma. *EClinicalMedicine*. 2021;42:101201. doi:10.1016/j.eclinm.2021.101201
- 27. Jiang Y, Zhang Z, Yuan Q, et al. Predicting peritoneal recurrence and disease-free survival from CT images in gastric cancer with multitask deep learning: a retrospective study. *Lancet Digit Health*. 2022;4(5):e340–e350. doi:10.1016/S2589-7500(22)00040-1
- Purcell Y, Sartoris R, Paradis V, Vilgrain V, Ronot M. Influence of pretreatment tumor growth rate on objective response of hepatocellular carcinoma treated with transarterial chemoembolization. J Gastroenterol Hepatol. 2020;35(2):305–313. doi:10.1111/jgh.14816
- 29. Xu J, Qin S, Wei H, Chen Y, Peng Y, Qi L. Prognostic factors and an innovative nomogram model for patients with hepatocellular carcinoma treated with postoperative adjuvant transarterial chemoembolization. *Anna Med.* 2023;55(1):2199219. doi:10.1080/07853890.2023.2199219
- 30. Young L, Tabrizian P, Sung J, et al. Survival analysis using albumin-bilirubin (ALBI) grade for patients treated with drug-eluting embolic transarterial chemoembolization for hepatocellular carcinoma. J Vasc Interv Radiol. 2022;33(5):510–517.e1. doi:10.1016/j.jvir.2022.02.005
- 31. Zhong B, Jiang J, Sun J, et al. Prognostic performance of the china liver cancer staging system in hepatocellular carcinoma following transarterial chemoembolization. J Clin Translat Hepatol. 2023;11(6):1321–1328. doi:10.14218/JCTH.2023.00099

Journal of Hepatocellular Carcinoma

Dovepress

Publish your work in this journal

The Journal of Hepatocellular Carcinoma is an international, peer-reviewed, open access journal that offers a platform for the dissemination and study of clinical, translational and basic research findings in this rapidly developing field. Development in areas including, but not limited to, epidemiology, vaccination, hepatitis therapy, pathology and molecular tumor classification and prognostication are all considered for publication. The manuscript management system is completely online and includes a very quick and fair peer-review system, which is all easy to use. Visit http://www.dovepress.com/testimonials.php to read real quotes from published authors.

Submit your manuscript here: https://www.dovepress.com/journal-of-hepatocellular-carcinoma-journal

f 🔰 in 🕨 DovePress

397